SCHEDULE 13G/A: BlackRock Discloses 5.7% Stake in Ionis Pharmaceuticals Through Latest SEC Filing
Beneficial Ownership Report
BlackRock, Inc. has filed an Amendment No. 3 to its Schedule 13G, disclosing a beneficial ownership of 5.7% of the common stock of IONIS PHARMACEUTICALS INC as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 9,066,517 shares of IONIS PHARMACEUTICALS INC common stock.
- This ownership represents 5.7% of the total outstanding common stock of IONIS PHARMACEUTICALS INC.
- BlackRock, Inc. holds sole voting power over 8,800,496 shares and sole dispositive power over 9,066,517 shares.
- The filing is an Amendment No. 3 to a Schedule 13G, indicating a passive investment purpose and not an intent to influence control of the issuer.
- The filing identifies several BlackRock subsidiaries through which the securities are held, including BlackRock Fund Advisors, BlackRock Advisors (UK) Limited, and BlackRock Fund Managers Ltd.
Sentiment
Score: 6
Explanation: The document is a factual disclosure of beneficial ownership by a major institutional investor. While not explicitly positive or negative about the issuer's performance, a significant and continued stake by BlackRock can be viewed as a neutral to slightly positive signal of investor confidence.
Positives
- BlackRock, Inc., a major institutional investor, maintains a significant beneficial ownership stake of 5.7% in IONIS PHARMACEUTICALS INC, which can be interpreted as a sign of continued confidence in the company's long-term prospects.
- The filing indicates a passive investment strategy, suggesting BlackRock is not seeking to influence the control of IONIS PHARMACEUTICALS INC, which can provide stability for the company's current management and strategic direction.
Negatives
- This Schedule 13G filing primarily reports beneficial ownership and does not contain information that would typically be categorized as negative regarding the issuer's performance or outlook.
Risks
- This Schedule 13G filing is a disclosure of beneficial ownership by an institutional investor and does not contain information regarding the risks associated with IONIS PHARMACEUTICALS INC's business or operations.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding IONIS PHARMACEUTICALS INC's future outlook.
Industry Context
Schedule 13G filings are mandatory disclosures by institutional investors who acquire more than 5% of a company's voting stock with a passive investment intent. BlackRock's continued significant stake in IONIS PHARMACEUTICALS INC indicates its ongoing position as a major shareholder in the biotechnology and pharmaceutical sector, reflecting its broad investment strategies across various industries.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. executed a new Power of Attorney on January 21, 2025, which expressly revokes a previous Power of Attorney dated April 30, 2023. This new document designates several individuals as attorneys-in-fact to execute and file various ownership and control-person reporting requirements on behalf of BlackRock and its affiliates. | 2025-01-21 | This change relates to BlackRock's internal corporate governance regarding its SEC filing procedures, ensuring authorized personnel can sign and submit required regulatory documents. It does not directly impact the corporate governance of IONIS PHARMACEUTICALS INC. |
Stakeholder Impact
- Shareholders: The disclosure of BlackRock's significant and continued stake may provide a degree of confidence to other shareholders, indicating a major institutional investor's long-term interest in IONIS PHARMACEUTICALS INC.
- Investment Professionals: Provides transparency into the ownership structure of IONIS PHARMACEUTICALS INC and BlackRock's investment portfolio.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of the previously revoked Power of Attorney for BlackRock, Inc. |
| 2025-01-21 | Date of execution for the new Power of Attorney by BlackRock, Inc. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G Amendment No. 3. |
| 2025-04-17 | Date of filing and signature for this Schedule 13G Amendment No. 3. |
Keywords
BlackRock, Ionis Pharmaceuticals, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management, Pharmaceuticals, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.